Wednesday, July 8, 2026

Patent intelligence · US

US 7666989

Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof

granted A61KA61K38/00A61PA61P35/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 4
Applicant portfolio 21
Patent details — US 7666989
Jurisdiction
US
Status
granted
Grant date
Feb 23, 2010
Expiration
Feb 18, 2030
Claims
7
CPC classes
A61K, A61K38/00, A61P, A61P35/00
View on Google Patents ↗

Quick answer

US 7666989 (Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof) is held by Beijing Sunbio Biotech Co. Ltd.. Status: granted. Granted Feb 23, 2010. Expires Feb 18, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
7
CPC classes
A61K, A61K38/00, A61P, A61P35/00

More from Beijing Sunbio Biotech Co. Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12234288

    Immunogenic arginase 2 polypeptides

    IO Biotech ApS · Expires Feb 20, 2045

    granted
  2. US 12233103

    Indoleamine 2,3-dioxygenase based immunotherapy

    IO Biotech ApS · Expires Feb 20, 2045

    granted
  3. US 12215135

    PDL2 compounds

    IO Biotech ApS · Expires Jan 30, 2045

    granted
  4. US 12194081

    ARGINASE1 polypeptides

    IO Biotech ApS · Expires Jan 9, 2045

    granted
  5. US 12187782

    PDL1 peptides for use in cancer vaccines

    IO Biotech ApS · Expires Jan 2, 2045

    granted
  6. US 12077785

    Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof

    SOTIO BIOTECH INC. · Expires Aug 29, 2044

    granted
  7. US 11981944

    Immunogenic arginase peptides

    IO Biotech ApS · Expires May 9, 2044

    granted
  8. US 11878053

    Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof

    IO Biotech ApS · Expires Jan 18, 2044

    granted

Frequently asked questions

What is US patent 7666989?

US 7666989 (Recombinant protein having an anti-cancer effect, its encoding gene and uses thereof) is held by Beijing Sunbio Biotech Co. Ltd.. Status: granted. Granted Feb 23, 2010. Expires Feb 18, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7666989?

Beijing Sunbio Biotech Co. Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.

When does US 7666989 expire?

Our index shows an expiration date of Feb 18, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.